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Abstract 
Background: While the effects of initiation of antiretroviral treatment (ART) on risky sexual behavior have been 
extensively studied, less is known about the long-term changes in risky sexual behavior over time in resource-poor 
settings.
Methods: We conducted a secondary longitudinal analysis of one rural and one urban cohort of patients who initi-
ated ART in Uganda between April 2004 and July 2007 followed up-to 2016. Data on sexual behavior were collected 
every 6 months for 3.5 years in individuals on ART ≥ 4 years (baseline) when a behavioral questionnaire was intro-
duced. Risky sexual behavior was defined as sexual intercourse with ≥ 2 partners or inconsistent or no condom use 
in previous 6 months. We report characteristics overall, and by cohort. We used multivariable generalized estimating 
equations logistic regression to assess the effects of time on ART on risky sexual behavior.
Results: Of 1012 participants, 402 (39.8%) were urban and 610 (60.2%) were rural residents. Mean age was 42.8 years 
(SD 8.5). Mean duration of follow-up was 51.3 months (SD 15.3), but longer for urban than rural participants (64.5 vs 
36.4 months). Risky sexual behavior declined from 33.1% at baseline to 9.6% after 3.5 years of follow-up in the rural 
cohort (p ≤ 0.01 for the test of trend) and was unchanged from 9.7% at baseline to 9.9% after 3.5 years in the urban 
cohort (p = 0.51). Receiving care at a rural clinic (aOR 4.99, 95% CI 3.64–6.84); male gender (aOR 1.66, 95% CI 1.26–2.19) 
and being younger (aOR 5.60, 95% CI 3.80–8.25 for 18–34 years and aOR 2.34, 95% CI 1.74–3.14 for 35–44 years) were 
associated with increased odds of risky sexual behavior. Not being married (aOR 0.25; 95% CI 0.19–0.34), and longer 
time on ART (aOR 0.71 95% CI 0.67–0.76) were associated with reduced odds of risky sex.
Conclusions: We observed a decline in risky sexual behavior in rural people on long-term (≥ 4 years) ART. Rural, 
male and young individuals had higher odds of self-reported risky sexual behavior. ART programs should continue to 
emphasize risk reduction practices, especially among people receiving care in rural health facilities, males, younger 
individuals and those who are married.
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Background
Antiretroviral therapy (ART) transforms HIV infection 
from a fatal disease to a chronic, manageable condition, 
increases the quality of life of people living with HIV, 
greatly improves survival, and reduces the risk of trans-
mission of HIV to a sexual partner [1–3]. Beginning in 
2004, ART use in sub-Saharan Africa was dramatically 
expanded using a public health approach, which led to a 
rapid expansion of access to treatment in resource-lim-
ited settings [1, 2, 4]. In 2017, an estimated 21.7 million 
people globally were on ART [1]. In Uganda, the num-
ber of people on ART is about 750,000 in 2014 [5]. The 
number of people on ART is likely to further increase 
following the “recent ‘Treat All’ recommendations by the 
World Health Organization (WHO) [2, 3]. The educa-
tional campaigns around reduced HIV transmission risk 
with suppressed viral load (Undetectable = Untransmit-
table UNAIDS message) and reduced HIV related mor-
bidity and mortality may change the sexual behaviour of 
persons receiving ART [6] as well as HIV negative indi-
viduals. Whilst the public discussion of ART prevention 
benefits has intensified in the framework of the WHO 
‘Treat All’ strategy, one of the issues voiced is that this 
might result in increased sexual risk-taking [6–10].
Prior studies have evaluated the association between 
ART and risky sexual behavior in the first one to 3 years 
following ART initiation. Prospective cohort studies in 
South Africa and Uganda found a decrease in risky sex-
ual behavior. In Uganda, risky sexual behavior in men 
decreased from 16.2% before ART to 4.3% at 12 months 
after ART initiation [11]. In South Africa, risky sexual 
behavior decreased 12  months after ART initiation 
compared to pre-ART (aOR 0.86, 95% CI 0.78–0.95) 
[12]. In a randomized clinical trial of three different 
ART monitoring strategies in rural Uganda, risky sexual 
activity decreased from 22% at ART initiation to 14% at 
36 months of ART follow up [13, 14]. In contrast, cross-
sectional studies from Togo, Uganda and Cote d’Ivoire 
found higher rates of participants practicing risky sexual 
behavior after short durations on ART [15–19]. These 
conflicting results highlight the complexity of examin-
ing the association of ART and risky sexual behavior and 
its variations in different settings, study participants and 
treatment program characteristics. Two meta-analyses 
summarized the association between ART and sexual 
risk behavior. A meta-analysis of 8 longitudinal stud-
ies and 6 cross-sectional studies of the sexual behavior 
of patients on ART in Sub Saharan Africa (SSA) found 
a reduction in risky sexual behavior as compared to pre-
ART (pooled effect estimate OR 0.47, 95% CI 0.25–0.89 
for multiple sexual partners). Furthermore, people on 
ART were 55% more likely to have protected sex with a 
partner who was HIV negative or of unknown HIV status 
as compared to an HIV infected partner [20]. Another 
meta-analysis of 55 prospective and cross-sectional stud-
ies in SSA also found lower sexual risk-taking (OR 0.7; 
95% CI 0.62–0.81) among participants on ART compared 
with those not on ART [21].
To date, most studies examined the effect of ART 
on sexual risk behavior in the first year(s) of ART; and 
mainly compared risky sexual behavior before and after 
ART initiation. Data on the risky sexual behavior among 
adults on long-term (≥ 4  years) ART in sub-Saharan 
Africa is limited. Using data from two clinical cohorts, 
we evaluated long-term changes in risky sexual behavior 
among people receiving ART in urban and rural Uganda.
Methods
Study design
This was a secondary analysis of two longitudinal cohorts 
of individuals on long-term ART: the ART cohort of The 
Infectious Diseases Institute (IDI), College of Health Sci-
ences at Makerere University in Kampala, Uganda [22] 
and the ART cohort of The AIDS Support Organization, 
(TASO) in Jinja, Uganda [23]. The two cohorts had a 
2-year difference in ART initiation timelines and this lim-
ited direct comparison.
Study setting
The IDI urban ART cohort in Kampala
The adult clinic of the Infectious Diseases Institute 
(IDI) is a Centre of excellence for HIV care and treat-
ment located in the Mulago Teaching Hospital in Kam-
pala-Uganda. IDI is a large outpatient clinic with over 
30,000 patients ever enrolled and cares for people living 
in five Kampala municipalities. ART is provided free of 
charge, initially through the Global Fund and later mainly 
through the US President’s Emergency Plan for AIDS 
Relief (PEPFAR).
Following written informed consent, adults 
(age ≥ 18  years) starting ART between April 2004 and 
April 2005 were enrolled and followed up (hereafter 
referred to as the IDI urban cohort). ART was started in 
patients with WHO Stage 4 or CD4 count ≤ 200 cells/ml, 
(according to national treatment guidelines implemented 
at that time), and consisted of stavudine (weight-adjusted 
and its use discontinued in 2013 in Uganda), lamivudine 
and nevirapine (fixed-dose combination) or zidovudine, 
lamivudine (fixed-dose combination) and efavirenz. A 
study doctor and adherence counsellor evaluated patients 
at study enrolment and every 6 months thereafter, while 
they attended the general clinic for monthly ART medi-
cation refills [22]. At each study visit, a physical exami-
nation was performed and information was recorded 
about HIV status of the partner(s), social support, and 
sexual history in the past month including promotion 
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of condom use, adherence using visual analogue scale, 
and reasons for non-adherence. ART was monitored 
every 6 months through viral load (VL) testing. Partici-
pants with a VL ≥ 1000 copies/ml were offered enhanced 
adherence counselling and support including a face-to-
face session to discuss the implications of unsuppressed 
viral load (VL). Adherence strategies used by the patient 
were reviewed, and an adherence action plan developed. 
Patients with two consecutive viral loads ≥ 1000 cop-
ies/ml were considered eligible for a second-line ART 
regimen.
The TASO rural ART cohort in Jinja
The AIDS Support Organization is one of the first and 
largest non-governmental organizations in SSA, provid-
ing treatment to over 98,000 patients in Uganda. Since 
2004, TASO Jinja, one of 11 TASO care facilities in 
Uganda, has cared for people living with HIV in the Jinja 
district within a radius of 75 km and currently provides 
ART to over 5000 people.
In June 2012, TASO Jinja initiated a prospective lon-
gitudinal cohort (Long-term Outcome on ART study) 
among patients who initiated ART between 2004 and 
2007 using the WHO Stage 4 or CD4 count ≤ 200 cells/
ml, (according to national treatment guidelines imple-
mented at that time), and consisted of stavudine (weight-
adjusted and its use discontinued in 2013 in Uganda). The 
Long-Term Outcomes on ART study recruited patients 
receiving first-line ART for a minimum of 4 years (here-
after referred to as the TASO rural cohort) [23, 24]. 
Between July 1, 2012, and December 31, 2013, all individ-
uals receiving first-line ART for at least 4 years were eli-
gible to participate in the cohort study and were included 
after written informed consent. Participants continued 
to receive adherence counselling and condom use from 
TASO counsellors and peer educators mostly in groups 
as part of routine care. From August 2014 until Janu-
ary 2015, enrollment was restricted to patients already 
on ART for at least 4  years with CD4 cell count ≤ 450 
cells/mm3 in order to over-sample for participants who 
may have virologic failure. All participants continued to 
receive routine comprehensive HIV care from the TASO 
service providers. Routine VL testing was not available at 
TASO Jinja at the time of the study but all participants 
received a VL test at enrollment. Participants with a 
VL ≥ 1000 copies/ml were offered enhanced adherence 
counselling and support including a face-to-face session 
to discuss the implications of unsuppressed VL, assess-
ment of the adherence strategies used by the patient, and 
development of an adherence action plan. VL was re-
assessed after 3 months.
Patients were followed up for additional 3.5  years. 
Every 6  months, cohort participants completed an 
interviewer-administered standardized questionnaire 
(adapted from the HAARP study) [24] to collect behav-
ioral and treatment outcomes. Laboratory monitor-
ing included CD4 counts and VL every 6  months. CD4 
counts were performed at the Jinja referral hospital 
regional laboratory. Plasma samples were stored in liq-
uid nitrogen and shipped to the MRC/UVRI laboratory 
in Entebbe, Uganda for VL testing and resistance testing.
Data collection and management
The IDI urban cohort data were directly collected into an 
electronic behavioral medical record by study counsel-
lors who provided risk reduction counselling including 
condom use promotion and periodically validated by a 
senior data manager. The TASO rural cohort, data were 
collected by the research assistants (counsellors) using an 
interview administered behavioral questionnaire but they 
did not provide counselling on condom use promotion. 
Data were double entered using Epi-Info and imported 
into Access for data management and storage. Labora-
tory test results were transmitted electronically from the 
MRC laboratory to the data Centre in TASO Jinja, manu-
ally entered in the study database.
For this study, data extracted from TASO and IDI 
database included socio-demographic information (age, 
gender, educational level, employment, and marital sta-
tus), ART start date and regimen, clinical data collected 
at enrollment, including WHO clinical stage, CD4 cell 
counts, viral load and sexual behavior (number of part-
ners in past 6  months and consistency of condom use) 
and adherence data at enrolment and subsequent clinic 
visits. Risky sexual behavior was defined as sexual inter-
course with ≥ 2 partners or sexual intercourse with 1 
partner and inconsistent condom use.
Statistical analysis
For this analysis, baseline was defined as the time of 
enrollment into the cohort which occurred after ≥ 4 year 
on ART (rural cohort) or at the 4-year on ART visit 
(urban cohort). For all patients included in the cohort, 
data was extracted for an additional 3.5  years after this 
baseline visit. All participants were followed until death, 
loss to follow up, transfer out, withdrawal of consent, or 
3.5 years after the “baseline” visit.
We described participants characteristics at base-
line overall, by gender and cohort (urban/IDI and rural/
TASO) using means and frequencies. Continuous varia-
bles were compared using an unpaired t-test or Wilcoxon 
rank sum test if not normally distributed. Pearson Chi-
square was used to compare categorical variables.
The main exposure of interest was time on ART (coded 
as 6-month periods). Other covariates of interest were 
the site, age, CD4 cell count, viral load, gender, education 
Page 4 of 9Okoboi et al. AIDS Res Ther           (2018) 15:15 
level, marital status, occupation, and ART regimen at 
baseline and calendar year of ART initiation. In order to 
examine the effect of long-term ART on sexual behav-
iors, separate analyses were performed. At baseline, we 
performed multivariable logistic regression and included 
variables in the initial model based on prior knowledge 
or association of the selected covariates with risky sexual 
behavior in bivariable analysis. Using a backwards elimi-
nation procedure, we started with all covariates in the 
model and then stepwise removed the covariate with 
the largest p-value until all the remaining covariates had 
a p-value less than 0.10 for the association with the out-
come of interest.
To model the association between the binary outcome 
(risky sexual behavior) and the exposure of time on ART, 
we used a Generalized Estimating Equations (GEE) logis-
tic regression model, with a logit link function to model 
the association between the binary outcome (risky sexual 
behavior) and the exposure of time on ART. Using a GEE 
logistic regression, odds ratios (ORs) were derived that 
took into account the repeated measures in individual 
participants and missing data in response variables, using 
robust standard errors to account for within-subject cor-
relation. Co-variates with a p-value less than 0.10 for the 
association with the outcome of interest was included in 
the final model. Data were analyzed using STATA version 
15 (StataCorp, College Station, TX).
Effect modifiers exploratory analysis
We assessed for effect modification by the following 
variables: gender and sexual partners, marital status and 
sexual partners, current age group and sexual partners. 
Interaction terms with a p-value < 0.05 were considered 
statistically significant.
Results
Overall, 1012 individuals receiving ART for ≥ 4  years 
were included in the analysis. Of these 402 (39.8%) were 
from the urban (IDI) cohort and 610 (60.2%) from the 
rural (TASO) cohort. Most patients were female (69.6% 
urban vs 75.7% rural cohort) and about half (53.3% urban 
vs 54.4% rural) of all patients were not married. At base-
line, the mean age was 42.8  years (SD = 8.5), with rural 
patients being older than urban patients (mean age 
44.6 vs 39.8  years; p-value 0.05) (Table  1). Slightly over 
a half (53.5%) of the urban but only 35.3% of the rural 
participants attained secondary education or higher 
(p-value < 0.01). At baseline, the most common ART regi-
men was zidovudine, lamivudine and nevirapine in the 
rural cohort and a tenofovir-based regimen in the urban 
cohort. At baseline, almost all participants (~ 90% in 
both cohorts) had a CD4 > 200 cells/mm3, but the mean 
CD4 count was lower in the urban cohort (mean CD4 
cell count 426 cells/mm3 and 564 cells/mm3 for urban 
cohorts and rural, respectively).
Follow up
A total of 941/1012 (93%) participants completed 
3.5 years of follow up after baseline. The mean duration 
of follow-up was 51.3  months (SD 15.3), but longer for 
urban than rural participants (64.5 vs 36.4 months). After 
Table 1 Baseline characteristics of the cohort participants
Some percentages do not add up to 100% because of missing data
Variable N Urban (IDI) N Rural (TASO)
N (%) N (%)
Baseline age in years 402 610
 18–34 118 (29.3) 52 (8.5)
 35–44 180 (44.8) 274 (44.9)
 > 45 104 (25.9) 284 (46.6)
Gender
 Female 280 (69.6) 462 (75.7)
 Male 122 (30.4) 148 (24.3)
Marital status
 Married/cohabiting 187 (46.5) 278 (46.6)
 Not married 215 (53.5) 332 (54.4)
Educational level
 No formal education 15 (3.7) 110 (18.0)
 Primary level 173 (43.0) 285 (46.7)
 ≥ Secondary level 214 (53.3) 215 (35.3)
Employment
 Formal employment 178 (44.3) 105 (17.6)
 No formal employment 224 (55.7) 491 (82.4)
Baseline ART regimen
 ZDV 3TC EFV 123 (33.5) 113 (18.5)
 D4T 3TC NVP 66 (18.0) 0
 ZDV 3TC NVP 0 356 (58.3)
 TDF based regimen 177 (48.5) 141 (23.0)
Mean time on ART 8.7 (SD 1.2) 7.0 (SD 0.3)
Baseline viral load
 Mean log 10 viral load cop-
ies/ml
2.65 (SD 0.34) 1.91 (SD 1.27)
 < 1000 cells/ml 385 (96) 501 (82.1)
 ≥ 1000 cells/ml 16 (4.0) 109 (17.9)
Baseline CD4 cell/mm3
 Mean CD4 426(SD 194.4) 564.3 (284.2)
 < 200 cells/mm3 43 (10.7) 54 (8.85)
 200–499 cells/mm3 237 (60.0) 213 (34.9)
 > 499 cells/mm3 122 (30.4) 340 (55.7)
WHO staging
 Stage 1 2 (0.5) 25 (4.2)
 Stage 2 51(12.7) 243 (41.3)
 Stage 3 232 (57.7) 205 (34.8)
 Stage 4 117 (29.1) 116 (19.7)
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enrollment, 38 (3.8%) participants died 21 (5.2%) urban 
and 17 (2.9%) rural participants. At 3.5 years of follow up, 
few (3.3%) patients were lost to follow up or transferred 
out (16 urban and 17 rural participants), and only 15 
(1.5%, all urban) participants withdrew study consent.
Risky sexual behavior at baseline (≥ 4 years visit on ART)
Overall, 241 (24.0%) cohort participants reported hav-
ing engaged in risky sexual behavior at baseline. The type 
of risky sexual behavior was predominantly inconsistent 
or no condom use while engaged in a sexual relation-
ship with a single partner (87.1%, 210/241). Engagement 
in sexual relationships with ≥ 2 partners was less preva-
lent (12.9%, 32/241). Participants reporting risky sexual 
behavior at baseline were more likely to be aged 18–34 
and 35–44  years, female, married, and rural residency 
(p < 0.01 for all) (Table 2).
In univariate logistic regression analysis, rural resi-
dence (OR 4.61, 95% CI 3.18–6.68), being male (OR 
2.16, 95% CI 1.58–2.94), formal employment (OR 1.54, 
95% CI 1.09–2.17), viral load > 1000 copies/ml (OR 1.22, 
95% CI 0.80–1.87), and being younger [18–34 years (OR 
1.11, 95% CI 0.72–1.72) and 35–44 years (OR 1.43, 95% 
CI 1.04–1.97) compared with age > 45 years] were associ-
ated with an increased odds of risky sexual behavior. Not 
being married was associated with lower odds of risky 
sexual behavior (OR 0.11, 95% CI 0.07–0.55).
In multivariable logistic analysis, rural residence 
(adjusted odds ratio [aOR] 9.54, 95% CI 5.83–15.61) 
being male (aOR 1.51, 95% CI 1.02–2.31) and younger 
age, (aOR 3.41, 95% CI 1.87–6.21 for 18–34  years and 
aOR 2.12, 95% CI 1.40–3.21 for 35–44  years) remained 
strongly associated with increased odds of risky sexual 
behavior. Not being married remained associated with 
lower odds of risky sexual behavior (aOR 0.10; 95% CI 
0.06–0.14) (Table 3).
Risky sexual behavior over time
The proportion of rural patients self-reporting risky sex-
ual behavior declined from 33.1% at enrollment to 9.6% at 
3.5 additional years of follow up (p-value for trend < 0.01). 
In contrast, the proportion of urban patients self-report-
ing risky sexual behavior remained stable: 9.7% at enroll-
ment, 11.2% at 1  year later, 12.6% at 2.5  years later and 
9.9% at 3.5 years later of follow up (p value for trend 0.71) 
(Fig. 1).
In the multivariable (GEE) logistic regression model, 
taking repeated measures over time into account, rural 
residence (aOR 4.99, 95% CI 3.64–6.83); male gender 
(aOR 1.66, 95% CI 1.26–2.19) and younger age; (aOR 
5.60 95% CI 3.80–8.25 for 18–34  years and aOR 2.34 
95% CI 1.74–3.14 for 35–44  years) were associated 
with increased odds of risky sexual behavior. Not being 
married (aOR 0.25, 95% CI 0.19–0.34) and time on ART 
(aOR 0.71 per year, 95% CI 0.67–0.66), baseline CD4 cell/
mm3 (aOR 0.59, 95% CI 0.38–0.90 for 200–499 cells/mm3 
and aOR 0.52 95% CI 0.33–0.84 for > 499 cells/mm3) were 
associated with reduced odds of risky sexual behavior 
(Table 3).
Educational level, type of employment, the age of first 
sexual intercourse (aOR 112; 95% CI 0.80–1.78) and 
number of lifetime sexual partners (aOR 0.95; 95% CI 
0.90–1.01) were not associated with risky sexual behavior.
Discussion
Among people on ART for ≥ 4  years we observed that 
rural residence was associated with increased odds of 
self-reported risky sexual behavior. Risky sexual behavior 
was predominately due to poor condom use and much 
Table 2 Baseline participants risky sexual behavior 
comparison
Variable N Non risky (N = 769) Risky sex (N = 241)
N (%) N (%)
Site 1010
 Urban 363 (47.2) 39 (16.2)
 Rural 406 (52.8) 202 (83.8)
Age in years 1010
 18–34 131 (17.1) 38 (15.8)
 35–44 331 (43.0) 127 (51.0)
 ≥ 45 307 (39.9) 80 (33.2)
Gender 1010
 Female 593 (77.0) 147 (61.0)
 Male 176 (23.0) 94 (39.0)
Marital status 1010
 Married/cohabiting 265 (34.5) 200 (90.0)
 Not married 504 (65.5) 41 (17.0)
Educational level 1010
 No formal educa-
tion
97 (12.6) 27 (11.2)
 Primary Level 343 (44.6) 114 (47.3)
 ≥ Secondary level 326 (42.8) 100 (41.5)
Employment 996
 Formal employ-
ment
231 (30.1) 57 (22.0)
 No formal employ-
ment
529 (69.9) 184 (80.0)
Baseline viral load 1009
 < 1000 cells/ml 678 (88.3) 207 (85.9)
 ≥ 1000 cells/ml 90 (11.7) 34 (14.1)
Baseline CD4 1010
 < 200 cells/mm3 71 (9.2) 29 (12.0)
 200–499 cells/mm3 355 (46.0) 95 (39.4)
 > 499 cells/mm3 345 (44.8) 117 (48.6)
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less due to multiple sexual partners. Risky sexual behav-
ior increased with younger age, with a 2.12-fold increased 
odds among 35–44  years and 3.41-fold higher odds 
among 18–34 years compared to individuals age 45 years 
or older. The odds of risky sexual behavior decreased with 
time of follow up on ART (aOR 0.71), but this decrease 
over time was only present in the rural cohort. When 
taking the sexual behavior over the entire period of long-
term ART into account, the odds of risky sexual behavior 
was higher among male compared to female participants 
(aOR 1.66), while a higher CD4 count (aOR 0.52–0.59) 
and those who failed to achieve viral load suppression 
(aOR 0.52) at baseline was associated with a lower odds 
of risky sexual behavior.
Comparison with other studies in sub-Saharan Africa 
is difficult as longitudinal data on risky sexual behaviors 
among people on long-term ART is limited. Our find-
ings do suggest that the reduction in risky sexual behav-
ior observed in the first year(s) of ART in several studies 
in sub-Saharan Africa [9, 12, 14, 20, 21, 25–31] does not 
revert into increased risky sexual behavior over time, 
but instead either stabilizes at a relatively low rate (as 
observed in the urban cohort) or further decreases over 
time (as observed in the rural cohort). Even though the 
risk reduced or stabilized over time, the continued risk-
taking emphasizes that it remains important to focus 
on individual risk reduction practices such as consistent 
condom use even among patients who are already several 
years on ART.
Table 3 Risky sexual behavior and associations with ART among cohort participants
Variable Baseline (≥ 4 years risky sexual behavior) GEE logistic analysis
Univariate logistic Multivariate logistic Un adjusted GEE Adjusted GEE
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI
Site
 Urban Ref Ref Ref Ref
 Rural 4.61 (3.18–6.68) 9.54 (5.83–15.61) 2.06 (1.58–2.70) 4.99 (3.64–6.83)
Baseline age in years
 18–34 1.11 (0.72–1.72) 3.41 (1.87–6.21) 2.58 (1.83–3.65) 5.60 (3.80–8.25)
 35–44 1.43 (1.04–1.97) 2.12 (1.40–3.21) 1.86 (1.39–2.49) 2.34 (1.74–3.14)
 > 45 Ref Ref Ref Ref
Gender
 Female Ref Ref Ref Ref
 Male 2.16 (1.58–2.94) 1.51 (1.0–2.31) 1.82 (1.41–2.35) 1.66 (1.26–2.19)
Marital status
 Married/cohabiting Ref Ref Ref Ref
 Not married 0.11(0.07–0.55) 0.09 (0.06–0.14) 0.26 (0.20–0.34) 0.25 (0.19–0.34)
Educational level
 No formal education Ref Ref
 Primary level 1.20 (0.74–1.94) 1.30 (0.85–1.99)
 ≥ Secondary level 1.10 (0.68–1.79) 1.45 (0.95–2.22)
Employment
 No formal employment Ref Ref Ref
 Formal employment 1.54 (1.09–2.17) 0.93 (0.60–1.44) 1.18 (0.89–1.55)
Viral load
 < 1000 cells/ml Ref Ref Ref Ref
 ≥ 1000 cells/ml 1.22 (0.80–1.87) 0.52 (0.23–0.96) 1.26 (0.88–1.79) 0.57 (0.37–0.87)
Baseline CD4
 <200 cells/mm3 Ref Ref Ref Ref
 200–499 cells/mm3 0.66 (0.49–1.07 0.57 (0.30–1.10 0.67 (0.45–0.99) 0.59 (0.38–0.90)
 >499 cells/mm3 0.51 (0.51–1.34) 0.63 (0.32–1.23) 0.62 (0.42–0.92) 0.52 (0.33–0.84)
Time on ART 0.76 (0.72–0.80) 0.71 (0.67–0.76)
TASO cohort sub-analysis
 No. of life time partners 1.00 (1.10–1.02) 1.01 (1.00–1.02)
 Age of first sex 0.98 (0.92–1.06) 1.02 (0.97–1.07)
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We found that rural residence, male gender, and 
younger age were associated with increased odds of 
risky sexual behavior, similar to what was observed in 
sub-Saharan Africa studies of individuals during the first 
one to 4 years of ART [11–14, 21, 27–29]. For example, 
in a South African cohort study, people receiving ART at 
urban and rural health care facilities found younger age, 
being married and male gender was associated with risky 
sexual behavior [12]. Our finding of increased risky sex-
ual behavior among males and married is also similar to 
Ugandan studies that found, among those on ART for one 
to 4 years, higher or even increased risky sexual behavior 
among men and those that are married were observed 
[11, 13, 14, 27, 30]. The increased risky sexual behavior 
observed among men could be because of the gender 
and power dynamics, where men are the major decision-
makers in sexual issues in Africa. Among the married, 
the increased risk of sexual behavior is attributed to the 
desire to have children, fear of HIV status disclosure to 
the sexual partner(s), and the beliefs that condom use is 
not necessary for HIV positive couples and reduces sex-
ual satisfaction. The difference in risky sexual behavior 
among people receiving care at urban and rural facilities 
could be due to differences in rural vs urban environment 
with urban participants having greater exposure to HIV 
prevention messaging and more likely to be of a higher 
socioeconomic status. Furthermore, condom promotion 
was mainly done to urban cohort participants.
The reduced odds of risky sexual behavior among par-
ticipants with higher CD4 cell/mm3 and suppressed VL 
at baseline is similar to the findings of other studies in 
Uganda [11, 13, 14, 27, 30].
Our study had several strengths, including its prospec-
tive design, the inclusion of a cohort in both a rural and 
urban setting, and the large sample size which allowed us 
to assess and identify factors that are independently asso-
ciated with risky sexual behavior. Several limitations need 
to be taken into account when interpreting the results. 
First, the two cohorts had a 2-year difference in ART ini-
tiation timelines and baseline visit included participants 
who have been on ART for 4 years in the urban cohort 
or ≥ 4  years in the rural cohort, complicating straight-
forward comparison between these two cohorts. Sec-
ond, only patients from HIV centers of excellence were 
included, which may not be representative for smaller 
centers or primary care settings. Furthermore, at the IDI 
(urban cohort), patients were asked about sexual behav-
ior from ART initiation by the counsellors which were 
providing risk-reduction counselling, which may lead to 
patients being less likely to report risky sexual behavior 
due to social desirability bias. However, the study team 
was trained to ask questions in a professional and non-
judgmental approach to minimize any social desirability. 
Third, patients included in the study initiated ART based 
on CD4 eligibility criteria hence our results may not be 
generalizable to people receiving long term–term ART 
under the current WHO ‘treat all’ strategy. Future studies 
should monitor trends of risky sexual behavior in high-
risk populations on long-term ART and whether low-risk 
sexual behavior also occurs among patients on long-term 
ART in the ‘treat all’ era.
Conclusions
We observed a decline in risky sexual behavior in rural 
people on long-term (≥ 4  years) ART. Rural, male and 
young individuals had higher odds of self-reported 
risky sexual behavior. ART programs should continue 
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to emphasize risk reduction practices, especially among 
people receiving care in rural health facilities, males, 
younger individuals and those who are married.
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